119 related articles for article (PubMed ID: 31907538)
1. Iron Overload Associated Endocrine Dysfunction Leading to Lower Bone Mineral Density in Thalassemia Major.
Yang WP; Chang HH; Li HY; Lai YC; Huang TY; Tsai KS; Lin KH; Lin DT; Jou ST; Lu MY; Yang YL; Chou SW; Shih SR
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31907538
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density among Palestinian patients suffering from hemoglobinopathy disorders.
Kharroubi A; Karmi B; Shamasneh W; Saba E
Arch Osteoporos; 2020 Nov; 15(1):181. PubMed ID: 33188480
[TBL] [Abstract][Full Text] [Related]
3. The impact of genotype on endocrine complications in thalassaemia major.
Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
[TBL] [Abstract][Full Text] [Related]
4. New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.
Carsote M; Vasiliu C; Trandafir AI; Albu SE; Dumitrascu MC; Popa A; Mehedintu C; Petca RC; Petca A; Sandru F
Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010271
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data.
Soliman AT; El Banna N; Abdel Fattah M; ElZalabani MM; Ansari BM
Metabolism; 1998 May; 47(5):541-8. PubMed ID: 9591744
[TBL] [Abstract][Full Text] [Related]
6. Gender differences in the prevalence and severity of bone disease in thalassaemia.
Kyriakou A; Savva SC; Savvides I; Pangalou E; Ioannou YS; Christou S; Skordis N
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():116-22. PubMed ID: 19337164
[TBL] [Abstract][Full Text] [Related]
7. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
Soliman AT; Yassin MA; De Sanctis V
Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
[TBL] [Abstract][Full Text] [Related]
8. Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables.
Baldini M; Marcon A; Ulivieri FM; Seghezzi S; Cassin R; Messina C; Cappellini MD; Graziadei G
Ann Hematol; 2017 Jun; 96(6):995-1003. PubMed ID: 28321531
[TBL] [Abstract][Full Text] [Related]
9. Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years.
van Santen SS; Olsson DS; van den Heuvel-Eibrink MM; Wijnen M; Hammarstrand C; Janssen JAMJL; Johansson G; van der Lely AJ; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1397-407. PubMed ID: 32145029
[TBL] [Abstract][Full Text] [Related]
10. Low bone mineral density in adolescents with beta-thalassemia.
Vogiatzi MG; Autio KA; Mait JE; Schneider R; Lesser M; Giardina PJ
Ann N Y Acad Sci; 2005; 1054():462-6. PubMed ID: 16339698
[TBL] [Abstract][Full Text] [Related]
11. Bone Mineral Density and Dickkopf-1 in Adolescents with Non-Deletional Hemoglobin H Disease.
Wiromrat P; Rattanathongkom A; Laoaroon N; Suwannaying K; Komwilaisak P; Panamonta O; Wongsurawat N; Nasomyont N
J Clin Densitom; 2023; 26(3):101379. PubMed ID: 37147222
[TBL] [Abstract][Full Text] [Related]
12. Thalassemia bone disease: a 19-year longitudinal analysis.
Wong P; Fuller PJ; Gillespie MT; Kartsogiannis V; Kerr PG; Doery JC; Paul E; Bowden DK; Strauss BJ; Milat F
J Bone Miner Res; 2014 Nov; 29(11):2468-73. PubMed ID: 24764138
[TBL] [Abstract][Full Text] [Related]
13. Bone status and HCV infection in thalassemia major patients.
Meloni A; Pistoia L; Maffei S; Ricchi P; Casini T; Corigliano E; Putti MC; Cuccia L; Argento C; Positano V; Pepe A; Cademartiri F; Vassalle C
Bone; 2023 Apr; 169():116671. PubMed ID: 36623757
[TBL] [Abstract][Full Text] [Related]
14. Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with β-thalassemia major: a case-control study.
Bansal D; Venkateshwaran S; Khandelwal N; Marwaha RK
Pediatr Blood Cancer; 2011 Mar; 56(3):409-12. PubMed ID: 21113944
[TBL] [Abstract][Full Text] [Related]
15. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
16. Bone involvement and mineral metabolism in Williams' syndrome.
Palmieri S; Bedeschi MF; Cairoli E; Morelli V; Lunati ME; Scillitani A; Carnevale V; Lalatta F; Barbieri AM; Orsi E; Spada A; Chiodini I; Eller-Vainicher C
J Endocrinol Invest; 2019 Mar; 42(3):337-344. PubMed ID: 30030744
[TBL] [Abstract][Full Text] [Related]
17. Risk of bone loss in men with multiple sclerosis.
Weinstock-Guttman B; Gallagher E; Baier M; Green L; Feichter J; Patrick K; Miller C; Wrest K; Ramanathan M
Mult Scler; 2004 Apr; 10(2):170-5. PubMed ID: 15124763
[TBL] [Abstract][Full Text] [Related]
18. Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia.
Vogiatzi MG; Autio KA; Schneider R; Giardina PJ
J Pediatr Endocrinol Metab; 2004 Oct; 17(10):1415-21. PubMed ID: 15526720
[TBL] [Abstract][Full Text] [Related]
19. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia.
Kurtoglu AU; Kurtoglu E; Temizkan AK
Endokrynol Pol; 2012; 63(4):260-3. PubMed ID: 22933160
[TBL] [Abstract][Full Text] [Related]
20. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study.
De Sanctis V; De Sanctis E; Ricchieri P; Gubellini E; Gilli G; Gamberini MR
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():174-80. PubMed ID: 19337174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
